The comparison of the effects of short-term growth hormone treatment in patients with achondroplasia and with hypochondroplasia
- PMID: 12733711
- DOI: 10.1507/endocrj.50.69
The comparison of the effects of short-term growth hormone treatment in patients with achondroplasia and with hypochondroplasia
Abstract
The effects of recombinant human growth hormone (rhGH) treatment for three years were compared in patients with achondroplasia (ACH) and hypochondroplasia (HCH), whose diagnosis had been confirmed by DNA analysis of the fibroblast growth factor receptor 3 gene. Height SDS (H-SDS) and height velocity SDS (HV-SDS) using the standard for ACH significantly improved during three-year treatment as compared with that before treatment in both ACH and HCH except HV-SDS in the third year. The improvement was much greater in HCH than in ACH. The mean increase H-SDS using the standard for ACH in three years in ACH (from -0.2 SD to 0.1 SD) is almost negligible but that in HCH (from 1.2 SD to 2.6 SD) can be estimated as effective clinically. It can be concluded short-term GH treatment in HCH is effective to increase growth rate and H-SDS, but it has little effect in ACH. Further studies would be required to confirm the other beneficial effects of GH treatment such as increase in bone mineral density in ACH and HCH and the effect on the final height.
Similar articles
-
Serum NT-proCNP levels increased after initiation of GH treatment in patients with achondroplasia/hypochondroplasia.Clin Endocrinol (Oxf). 2016 Jun;84(6):845-50. doi: 10.1111/cen.13025. Epub 2016 Feb 25. Clin Endocrinol (Oxf). 2016. PMID: 26814021
-
Effect of growth hormone therapy in children with achondroplasia: growth pattern, hypothalamic-pituitary function, and genotype.Eur J Endocrinol. 1998 Mar;138(3):275-80. doi: 10.1530/eje.0.1380275. Eur J Endocrinol. 1998. PMID: 9539301 Clinical Trial.
-
Treatment of achondroplasia with growth hormone: six years of experience.Pediatr Res. 1999 Oct;46(4):435-9. doi: 10.1203/00006450-199910000-00012. Pediatr Res. 1999. PMID: 10509364
-
Height Outcome of Recombinant Human Growth Hormone Treatment in Achondroplasia Children: A Meta-Analysis.Horm Res Paediatr. 2016;86(1):27-34. doi: 10.1159/000446958. Epub 2016 Jun 30. Horm Res Paediatr. 2016. PMID: 27355624 Review.
-
Skeletal dysplasia, growth hormone treatment and body proportion: comparison with other syndromic and non-syndromic short children.Horm Res. 2003;60 Suppl 3:65-70. doi: 10.1159/000074504. Horm Res. 2003. PMID: 14671400 Review.
Cited by
-
Burden and Treatment of Achondroplasia: A Systematic Literature Review.Adv Ther. 2023 Sep;40(9):3639-3680. doi: 10.1007/s12325-023-02549-3. Epub 2023 Jun 29. Adv Ther. 2023. PMID: 37382866 Free PMC article. Review.
-
Analysis of the clinical and molecular characteristics of a child with achondroplasia: A case report.Exp Ther Med. 2015 May;9(5):1763-1767. doi: 10.3892/etm.2015.2324. Epub 2015 Mar 2. Exp Ther Med. 2015. PMID: 26136890 Free PMC article.
-
Achondroplasia: Development, pathogenesis, and therapy.Dev Dyn. 2017 Apr;246(4):291-309. doi: 10.1002/dvdy.24479. Epub 2017 Mar 2. Dev Dyn. 2017. PMID: 27987249 Free PMC article. Review.
-
Growth patterns and the use of growth hormone in the mucopolysaccharidoses.J Pediatr Rehabil Med. 2010;3(1):25-38. doi: 10.3233/PRM-2010-0106. J Pediatr Rehabil Med. 2010. PMID: 20563263 Free PMC article.
-
Interventions for improving clinical outcomes and health-related quality-of-life for people living with skeletal dysplasias: an evidence gap map.Qual Life Res. 2023 Oct;32(10):2751-2762. doi: 10.1007/s11136-023-03431-z. Epub 2023 Jun 9. Qual Life Res. 2023. PMID: 37294397 Free PMC article. Review.
